Diarrhea - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 95 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Diarrhea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2014', provides an overview of the Diarrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diarrhea Overview 9
Therapeutics Development 10
Pipeline Products for Diarrhea - Overview 10
Pipeline Products for Diarrhea - Comparative Analysis 11
Diarrhea - Therapeutics under Development by Companies 12
Diarrhea - Therapeutics under Investigation by Universities/Institutes 14
Diarrhea - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diarrhea - Products under Development by Companies 18
Diarrhea - Products under Investigation by Universities/Institutes 19
Diarrhea - Companies Involved in Therapeutics Development 20
Ipsen S.A. 20
Novartis AG 21
A. Menarini Industrie Farmaceutiche Riunite Srl 22
Mucosis B.V. 23
Helsinn Healthcare S.A. 24
Ventria Bioscience 25
Ache Laboratorios Farmaceuticos S/A 26
GP Pharm, S.A. 27
Syntiron LLC 28
Tioga Pharmaceuticals, Inc. 29
Intercept Pharmaceuticals, Inc. 30
Aegis Therapeutics, LLC 31
Drais Pharmaceuticals, Inc. 32
DiscoveryBiomed, Inc. 33
DesignMedix, Inc. 34
Chongqing Zhifei Biological Products Co., Ltd. 35
Sanofi Pasteur SA 36
Diarrhea - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
ibodutant - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
asimadoline - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
talactoferrin alfa - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
lanreotide acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
elsiglutide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
obeticholic acid - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ASP-7147 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
iOWH0-32 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ETEC Adhesin-Based Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
octreotide acetate MAR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ACH-04 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Diarrhea Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
octreotide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
INX-201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine for Bacterial Diarrhea - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
UDCA Analogues for Diarrheal Diseases - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
escherichia coli vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
yersinia pestis vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Bacterial Infections - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules for Diarrhoea - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Diarrhea - Recent Pipeline Updates 75
Diarrhea - Dormant Projects 84
Diarrhea - Discontinued Products 85
Diarrhea - Product Development Milestones 86
Featured News & Press Releases 86
Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 86
May 06, 2014: Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week 87
Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation 88
Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy 88
Oct 06, 2013: Ventria Bioscience to Present at the XIth International Conference on Lactoferrin 89
May 28, 2013: Helsinn And Zealand Pharma Announce Decision To Advance Development Of Elsiglutide Into Phase IIb For Prevention Of Chemotherapy-induced Diarrhea 90
May 28, 2013: Antidiarrheal drug candidate moves to next phase of clinical study 91
May 20, 2013: Intercept Pharma Announces Positive Initial Results From Ongoing Phase IIa Trial In Chronic Bile Acid Diarrhea 92
Nov 12, 2012: PATH's Drug Development Program Announces Positive Phase I Results For Anti-diarrheal Medication 92
Nov 12, 2012: Path Announces Positive Phase I Results Of iOWH032 To Treat Acute Secretory Diarrhea 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables
Number of Products under Development for Diarrhea, H2 2014 10
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Diarrhea - Pipeline by Ipsen S.A., H2 2014 20
Diarrhea - Pipeline by Novartis AG, H2 2014 21
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 22
Diarrhea - Pipeline by Mucosis B.V., H2 2014 23
Diarrhea - Pipeline by Helsinn Healthcare S.A., H2 2014 24
Diarrhea - Pipeline by Ventria Bioscience, H2 2014 25
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 26
Diarrhea - Pipeline by GP Pharm, S.A., H2 2014 27
Diarrhea - Pipeline by Syntiron LLC, H2 2014 28
Diarrhea - Pipeline by Tioga Pharmaceuticals, Inc., H2 2014 29
Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 30
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2014 31
Diarrhea - Pipeline by Drais Pharmaceuticals, Inc., H2 2014 32
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2014 33
Diarrhea - Pipeline by DesignMedix, Inc., H2 2014 34
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 35
Diarrhea - Pipeline by Sanofi Pasteur SA, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Diarrhea Therapeutics - Recent Pipeline Updates, H2 2014 75
Diarrhea - Dormant Projects, H2 2014 84
Diarrhea - Discontinued Products, H2 2014 85